Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$8.97MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Markus Warmuth
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 173
- Beta
- 1.37
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.54
Financials
Revenue
$8.97M+742.9%Net Income
$-43.40MEBITDA
$-41.27MFree Cash Flow
$-48.84MEPS (diluted)
$-0.51Shares Outstanding (diluted)
85.23M+292.1%Operating Expenses
$58.10MCash & Debt
$621.10MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $123.67M | $-38.63M | $-0.59 |
| 2024 | $75.62M | $-72.70M | $-0.98 |
| 2023 | $0.00 | $-135.35M | $-2.63 |
| 2022 | $0.00 | $-108.50M | $-2.30 |
| 2021 | $0.00 | $-73.96M | $-1.59 |
| 2020 | $0.00 | $-35.88M | $-0.82 |
| 2019 | $0.00 | $-8.02M | $-0.18 |
Valuation
GLUEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·17d ago·Positive
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
View source ↗ - Newsseekingalpha.com·45d ago·Negative
…ip asset MRT-6160. MRT-6160, targeting autoimmune diseases, offers differentiated safety and oral convenience, with Phase 2 results as the key near-term catalyst for GLUE. GLUE maintains a robust $626 million cash position, providing a 3.5-year runway and cushioning downside risk amid high clinical trial expenses.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D.
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.24 per share
Typical surprise -1.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.43 vs $-0.38miss
- Thu, May 7$-0.45 vs $-0.28miss
- Tue, Mar 17$-0.54 vs $-0.35miss
- Thu, Nov 6$-0.33 vs $-0.37beat
- Thu, Aug 7$-0.15 vs $-0.38beat
- Thu, May 8$0.57 vs $-0.00beat
Estimates and results for GLUE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GLUE officers and directors.
- Bought
- —
- Sold
- $4.1m
0 trades
36 trades
- Bowen Matthewsold
- Warmuth Markussold
- Champoux Jennifersold
- Townson Sharonsold
- Townson Sharonsold
- Janku Filipsold
- Janku Filipsold
- Manning Anthony M.sold
64 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GLUE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.